A regulação do preço dos medicamentos em Portugal

• Autor(a) principal: Martins, Filipe Costa
• Data de Publicação: 2020
• Tipo de documento: Dissertação
• Idioma: por
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: http://hdl.handle.net/10362/111194
• topic: Medicamentos; Serviço Nacional de Saúde; Sustentabilidade financeira; Regulação; Formação de preços; Regimes de comparticipação; Análise; Medicines; National Health Service; Financial sustainability; Regulation; Price and reimbursement rules; Economic analysis; Pharmaceutical industry; Direito

Medicines are a fundamental contribution to the health of citizens. However, as a result of scientific and technological advances in this field and the increase in the prevalence of chronic diseases, there is a constant growth in expenditure on medicines. The National Health Service, as a financing entity for the purchase of medicines, requires an efficient management in order to ensure its financial sustainability so that taxpayers do not see their taxes increased due to growing health care costs. In this context, regulation of the medicine sector proves to be essential not only to guarantee the quality and safety of medicines, but also to promote their accessibility through the application of price and reimbursement rules. In this study, it was also considered essential to be aware of models that may constitute valid alternatives to the current price system of medicines in Portugal, seeking its continuous improvement and increasing cost rationalization. Another important issue is the need for an efficient regulation of the sector to be able to find the necessary balance between cost control and the creation of incentives for research and development of new therapies. For this purpose we considered useful to make an economic analysis of the most relevant aspects of the pharmaceutical industry to grasp the impact of regulatory activity, both from a legal and economic point of view.